Suchergebnisse - "Ebada, Mohamed"

PubPharm (23)

1

Retraction Note : High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

enthalten in: Archives of virology | 2024

von Said, E. | Abdulaziz, B. | Kassas, M. | +3

RetractionOf: Arch Virol. 2020 Jul;165(7):1633-1639. - PMID 32356185

2

Retraction Note: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

enthalten in: Archives of virology | 2024

von Said, E. | Abdulaziz, B. | Kassas, M. | +3

3

Spectrum of Thoracic Imaging Findings in the Setting of Substance Abuse

enthalten in: Journal of computer assisted tomography | 2024

von Gann, L. | Kunin, J. | Ebada, M. | +1

4

Efficacy of Hibiscus sabdariffa on Reducing Blood Pressure in Patients With Mild-to-Moderate Hypertension : A Systematic Review and Meta-Analysis of Published Randomized Controlled Trials

enthalten in: Journal of cardiovascular pharmacology | 2022

von Abdelmonem, M. | Ebada, M. | Diab, S. | +8

5

Clinical profiles and outcomes of acute ST-segment elevation myocardial infarction in young adults in a tertiary care center in Saudi Arabia

enthalten in: Saudi medical journal | 2021

von Sakr, H. | Azazy, A. | Hillani, A. | +5

6

Clinical Importance of Incidental Homogeneous Renal Masses That Measure 10-40 mm and 21-39 HU at Portal Venous Phase CT : A 12-Institution Retrospective Cohort Study

enthalten in: AJR. American journal of roentgenology | 2021

von Corwin, M. | Altinmakas, E. | Asch, D. | +22

CommentIn: J Urol. 2022 Jan;207(1):208. - PMID 34662204

7

High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy : a real-life experience

enthalten in: Archives of virology | 2020

von Said, E. | Abdulaziz, B. | El Kassas, M. | +3

RetractionIn: Arch Virol. 2024 Feb 13;169(3):45. - PMID 38349452

8

High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

enthalten in: Archives of virology | 2020

von Said, E. | Abdulaziz, B. | El Kassas, M. | +3

9

High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

enthalten in: Archives of virology | 2020

von Said, E. | Abdulaziz, B. | El Kassas, M. | +3

10

RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

enthalten in: Archives of virology | 2020

von Said, E. | Abdulaziz, B. | El Kassas, M. | +3